Wells Fargo Maintains Equal-Weight on bluebird bio, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu maintains an Equal-Weight rating on bluebird bio (NASDAQ:BLUE) but lowers the price target from $3 to $2.
September 25, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has maintained its Equal-Weight rating on bluebird bio but has lowered the price target from $3 to $2, indicating a less optimistic outlook.
The lowering of the price target from $3 to $2 by Wells Fargo suggests a less optimistic view on bluebird bio's future performance, which could negatively impact the stock price in the short term. The Equal-Weight rating indicates a neutral stance, but the reduced price target is a bearish signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100